BeiGene is developing a pipeline of oral small molecules and monoclonal antibodies to treat cancer. Get up to date with the BeiGene solid tumor pipeline and clinical trials.

A short summary describing an anti-PD-1 antibody which is the backbone of a suite of immunotherapy combinations designed to avoid tumor resistance.

A short summary describing a unique OX40 agonist that does not block native ligand binding.

A short summary describing an antibody targeting TIM-3 which enhances T cell activity and NK-cell tumor cytotoxicity and may help overcome anti-PD-1 resistance in solid tumors.